HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purported ‘Cancer Cure’ Linked To Heart Toxicity Is US FDA’s Latest Warning Target In Supplements

Executive Summary

The ingredient, cesium chloride, also was the subject of a citizen petition by consumer advocacy group Public Citizen asking the FDA to prohibit its use in supplements. The FDA has warned five firms marketing products labeled as supplements and containing cesium chloride.

You may also be interested in...



FDA Strengthens Compounding Safety with Cesium Ban And Research Collaboration

FDA has taken additional steps to make drug compounding safer for patients, including a ban on cesium chloride because of “significant safety risks” it poses and a pair of university research collaborations to help further develop a list of bulk drug ingredients that can be safely compounded.

SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements

FDA warns three US firms marketing products labeled as dietary supplements but containing selective androgen receptor modulators, SARMs, anabolic steroid-like ingredients that have the potential to increase the risk of heart attack and stroke and for which long-term effects are unknown.

CBD Firm Targeting Veterans, Military Takes Broadside On COVID Claims From US Agencies

FTDA and FTC warn Patriot Supreme about noncompliant claims on its website and social media pages promoting CBD to prevent or treat infections from the coronavirus. However, a release Patriot Supreme distributed in July promoting CBD as a COVID-19 remedy remains in online circulation.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel